Dey is a pharmaceutical company that specializes in developing and manufacturing prescription drug products, such as EpiPen, EMSAM and Perforomist, for the treatment of respiratory disease, severe allergic reactions and psychiatric disorders.
Federal regulations place limits on the amount Wisconsin Medicaid can pay for reimbursement of prescription drugs. In order comply with those limits, Wisconsin estimates the acquisition cost providers pay to obtain prescription drugs that are later prescribed to Medicaid recipients. The state relies on average wholesale prices published by a pricing compendium, First DataBank. Wisconsin alleged Dey manufacturers reported inflated average wholesale prices to First DataBank in order to deceive the Medicaid pharmaceutical reimbursement program for increased sales and market share.
Read the AG’s news release about Dey’s settlement.
Read other coverage about pharmaceutical company settlements:
– Pharmaceutical Company to Pay $27M for Medicaid Fraud
– Pharmaceutical Company Teva Settles Drug-Pricing Lawsuits
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.